(Q38121015)

29 August 2017

Trametinib: first global approval (English)

1 reference

29 August 2017

1 reference

ChEBI release 2020-05-28

Cameron J M Wright

1

1 reference

PubMed ID

23846731

29 August 2017

Paul L McCormack

series ordinal

2

1 reference

29 August 2017

1 July 2013

1 reference

29 August 2017

1 reference

29 August 2017

73

1 reference

29 August 2017

11

1 reference

29 August 2017

1245-1254

1 reference

https://scigraph.springernature.com/pub.10.1007/s40265-013-0096-1

29 August 2017

0 references

cites work

NRAS mutation status is an independent prognostic factor in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0096-1

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0096-1

Update on the targeted therapy of melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0096-1

Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0096-1

Improved survival with MEK inhibition in BRAF-mutated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0096-1

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0096-1

Identification and characterization of a novel chemotype MEK inhibitor able to alter the phosphorylation state of MEK1/2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0096-1

Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0096-1

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0096-1

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0096-1

Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0096-1

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0096-1

Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0096-1

Novel MEK inhibitor trametinib and other retinoblastoma gene (RB)-reactivating agents enhance efficacy of 5-fluorouracil on human colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0096-1

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0096-1

A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0096-1

Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23846731

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S40265-013-0096-1

1 reference

PubMed ID

23846731

Dimensions Publication ID

29 August 2017

0 references

1 reference

PubMed ID

23846731